Search Results - bira+arya

4 Results

Sort By:

Novel Chemoattractant-Based Toxins To Improve Vaccine Immune Responses for Cancer and Infectious Diseases

Abstract: Cancer is one of the leading causes of death in United States and it is estimated that there will be more than half a million deaths caused by cancer in 2009. A major drawback of the current chemotherapy-based therapeutics is the cytotoxic side-effects associated with them. Thus there is a dire need to develop new therapeutic strategies...

Published: 4/8/2024 | Inventor(s): Bira Arya, Kouji Matsushima, Dolgor Bataar

Keywords(s): AIDS/HIV, Chemoattractant toxins, Immune Diseases, immunosuppressant, T regulatory (Treg) cells, TUBERCULOSIS

Category(s): TherapeuticArea > Immunology, TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Licensing

Immunogenic Antigen Selective Cancer Immunotherapy

Abstract: Melanoma is a particularly aggressive form of cancer primarily caused by over-exposure to sunlight. Although melanoma can strike at any age, the malignancy disproportionately impacts persons of advanced age, as these individuals often have decades of repeated exposure to harmful levels of ultraviolet radiation. Scientists at NIH among others...

Published: 4/8/2024 | Inventor(s): Bira Arya, Vladimir Larionov

Keywords(s): MELANOMA, POLYPEPTIDES, SPANX-B

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

Novel Regulatory B cells for Treatment of Cancer and Autoimmune Disease

Abstract: The manner by which cancers evade the immune response is not well-understood. What is known is that the manner is an active process that regulates immune responses employing at least two types of suppressive cells, myeloid-derived suppressive cells and regulatory T cells (Tregs), a key subset of CD4+ T cells that controls peripheral tolerance...

Published: 8/14/2024 | Inventor(s): Bira Arya, Purevdorj Olkhanud, Ioana Bodogai

Keywords(s): IMMUNOTHERAPEUTIC, Immunotherapy, suppressive regulatory B cells, tBregs

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Vaccines

Transformation of Weak or Non-Immunogenic Antigens to Produce an Immune Response and Therapeutic Polypeptides for the Treatment and Prevention of Cancer

Abstract: A significant challenge in developing therapies for the treatment and prevention of cancer has been the discovery, selection, and exploitation of antigens. Researchers at the National Institute on Aging (NIA) have partially circumvented this issue in their development of novel strategies for rendering weakly or non-immunogenic, shared antigens...

Published: 4/8/2024 | Inventor(s): Bira Arya, Dan Longo, Igor Espinoza-Delgado

Keywords(s): ANTIGEN, Biragyn, CANCER VACCINE, Chemokine, National Institute on Aging, NIA

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Collaboration Sought > Licensing, Application > Therapeutics